Cancer associates with risk and severe events ofCOVID-19: A systematic review and meta-analysis

Evidence is mounting to indicate that cancer patients may have more likelihood of having coronavirus disease 2019 (COVID-19) but lack consistency. A robust estimate is urgently needed to convey appropriate information to the society and the public, in the time of ongoing COVID-19 pandemic. We performed a systematic review and meta-analysis through a comprehensive literature search in major databases in English and Chinese, and two investigators conducted publication selection and data extraction independently. A meta-analysis was used to obtain estimates of pooled prevalence of cancer in patients with COVID-19 and determine the association of cancer with severe events, after assessment of potential heterogeneity, publication bias, and correction for the estimates when necessary. Total 38 studies comprising 7094 patients with COVID-9 were included; the pooled prevalence of cancer was estimated at 2.3% (95% confidence limit [CL] [0.018, 0.029];P < .001) overall and 3.2% (95% CL [0.023, 0.041];P < .001) in Hubei province; the corresponding estimates were 1.4% and 1.9% after correction for publication bias; cancer was significantly associated with the events of severe cases (odds ratio [OR] = 2.20, 95% CL [1.53, 3.17];P < .001) and death (OR = 2.97, 95% CL [1.48, 5.96];P= .002) in patients with COVID-19, there was no significant heterogeneity and a minimal publication bias. We conclude that cancer comorbidity is associated with the risk and severe events of COVID-19; special measures should be taken for individuals with cancer.

Automated summary

The study found that cancer patients may have a higher likelihood of contracting COVID-19, with a pooled prevalence of 2.3% overall and 3.2% in Hubei province. Cancer comorbidity is significantly associated with severe events and death in COVID-19 patients, highlighting the need for special measures for individuals with cancer.